MRTX849 (Adagrasib) is the second KRAS-G12C-mutant selective inhibitor to be approved by the FDA, indicated for the treatment of KRAS G12C-mutated NSCLC [37]. The gene discussed is KRAS; the disease is non-small cell lung carcinoma.